Metformin and other antidiabetic agents in renal failure patients

Kidney International

Volumn 87, Issue 2, 2015, Pages 308-322

  Lalau, Jean Daniel ^a,b   Arnouts, Paul ^c   Sharif, Adnan ^d   De Broe, Marc E ^e  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c AZ Turnhout ^*  (Belgium)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^e UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

antidiabetic agents; chronic kidney disease; lactic acidosis; metformin; pharmacokinetics; Type 2 diabetes

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; HUMAN INSULIN; INCRETIN; INSULIN; METFORMIN; NATEGLINIDE; ORGANIC CATION TRANSPORTER; PIOGLITAZONE; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; GLYCOSIDASE INHIBITOR;

ANTIDIABETIC ACTIVITY; BLOOD PH; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; GLOMERULUS FILTRATION RATE; GLUCONEOGENESIS; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LACTIC ACIDOSIS; NONHUMAN; PRESCRIPTION; PROGNOSIS; RENAL PROTECTION; REVIEW; RISK BENEFIT ANALYSIS; URINARY EXCRETION; ACIDOSIS, LACTIC; ADVERSE EFFECTS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; METABOLISM; RENAL INSUFFICIENCY;

ACIDOSIS, LACTIC; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; KIDNEY TRANSPLANTATION; METFORMIN; RENAL INSUFFICIENCY; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84922253642     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.19     Document Type: Review

References (136)

1. Prikis M, Mesler EL, Hood VL et al. When a friend can become an enemy! Recognition and management of metformin-Associated lactic acidosis. Kidney Int 2007; 72: 1157-1160.
2. Group UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
3. Fitzgerald M. The lactic acid myths. Competitor 2012; running.competitor.com/2010/01/training/the-lactic-Acid-myths-7938. Accessed: 25 February 2014.
4. Robergs RA, Ghiasvand F, Parker D. Biochemistry of exercise-induced metabolic acidosis. Am J Physiol Regul Integr Comp Physiol 2004; 287: R502-R516.
5. Kravitz L. Lactate not guilty as charged. www.drlenkravitz.com/Articles/ lactatearticle.html. Accessed: 8 February 2013.
6. Gevers W. Generation of protons by metabolic processes in heart cells. J Mol Cell Cardiol 1977; 9: 867-874.
7. Overgaard K, Nielsen OB. Activity-induced recovery of excitability in K(+)-depressed rat soleus muscle. Am J Physiol Regul Integr Comp Physiol 2001; 280: R48-R55.
8. Graham GG, Punt J, Arora M et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011; 50: 81-98.
9. Bardin C, Nobecourt E, Larger E et al. Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus. Eur J Clin Pharmacol 2012; 68: 961-968.
10. Kimura N, Masuda S, Tanihara Y et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005; 20: 379-386.
11. Gong L, Goswami S, Giacomini KM et al. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 2012; 22: 820-827.
12. Zolk O. Disposition of metformin: variability due to polymorphisms of organic cation transporters. Ann Med 2012; 44: 119-129.
13. Wang DS, Jonker JW, Kato Y et al. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002; 302: 510-515.
14. Shu Y, Sheardown SA, Brown C et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422-1431.
15. Christensen MM, Brasch-Andersen C, Green H et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011; 21: 837-850.
16. Zhou K, Bellenguez C, Spencer CC et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011; 43: 117-120.
17. van Leeuwen N, Nijpels G, Becker ML et al. A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-Analysis of five cohorts. Diabetologia 2012; 55: 1971-1977.
18. Wang ZJ, Yin OQ, Tomlinson B et al. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 2008; 18: 637-645.
19. Nies AT, Hofmann U, Resch C et al. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS One 2011; 6: e22163.
20. Nies AT, Koepsell H, Winter S et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 2009; 50: 1227-1240.
21. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994; 24: 49-57.
22. Robert F, Fendri S, Hary L et al. Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. Diabetes Metab 2003; 29: 279-283.
23. Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006; 49: 434-441.
24. Zhou G, Myers R, Li Y et al. Role of AMP-Activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
25. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000; 348(Pt 3): 607-614.
26. Foretz M, Hébrard S, Leclerc J et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010; 120: 2355-2369.
27. Miller RA, Birnbaum MJ. An energetic tale of AMPK-independent effects of metformin. J Clin Invest 2010; 120: 2267-2270.
28. Viollet B, Guigas B, Sanz Garcia N et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122: 253-2570.
29. Miller RA, Chu Q, Xie J et al. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013; 494: 256-260.
30. Wiernsperger NF. Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes. Diabetes Metab 1999; 25: 110-127.
31. Batandier C, Guigas B, Detaille D et al. The ROS production induced by a reverse-electron flux at respiratory complex 1 is hampered by metformin. J Bioenerg Biomembr 2006; 38: 33-42.
32. Detaille D, Guigas B, Chauvin C et al. Metformin prevents high-glucoseinduced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 2005; 54: 2179-2187.
33. Christiansen CF, Johansen MB, Christensen S et al. Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study. Crit Care 2013; 17: R192.
34. Morales AI, Detaille D, Prieto M et al. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. Kidney Int 2010; 77: 861-869.
35. Louro TM, Matafome PN, Nunes EC et al. Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats. Eur J Pharmacol 2011; 653: 89-94.
36. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
37. Radziuk JD, Zhang Z, Wiernsperger N et al. Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes 1997; 46: 1406-1413.
38. Dell'Aglio DM, Perino LJ, Kazzi Z et al. Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature. Ann Emerg Med 2009; 54: 818-823.
39. Lalau JD, Mourlhon C, Bergeret A et al. Consequences of metformin intoxication. Diabetes Care 1998; 21: 2036-2037.
40. Wang DS, Kusuhara H, Kato Y et al. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 2003; 63: 844-848.
41. Toyama K, Yonezawa A, Masuda S et al. Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis. Br J Pharmacol 2012; 166: 1183-1191.
42. Dykens JA, Jamieson J, Marroquin L et al. Biguanide-induced mitochondrial dysfonction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol 2008; 233: 203-210.
43. Protti A, Russo R, Tagliabue P et al. Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication. Crit Care 2010; 14: R22.
44. Protti A, Fortunato F, Monti M et al. Metformin overdose, but not lactic acidosis per se, inhibits oxygen consumption in pigs. Crit Care 2012; 16: R75.
45. Protti A, Lecchi A, Fortunato F et al. Metformin overdose causes platelet mitochondrial dysfunction in humans. Crit Care 2012; 16: R180.
46. Lalau JD, Race J. Metformin and lactic acidosis in diabetic humans. Diabetes Obes Metab 2000; 2: 131-137.
47. Umehara KI, Iwatsubo T, Noguchi K et al. Functional involvement of organic cation transporter1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats. Xenobiotica 2007; 37: 818-831.
48. Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf 2010; 33: 727-740.
49. Lalau JD, Race J. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-Associated lactic acidosis'. Diabetes Obes Metab 2001; 3: 195-201.
50. Kajbaf F, Lalau JD. The criteria for metformin-Associated lactic acidosis: the quality of reporting in a large pharmacovigilance database. Diabet Med 2013; 30: 345-348.
51. Stades AM, Heikens JT, Erkelens DW et al. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med 2004; 255: 179-187.
52. Lalau JD, Lemaire-Hurtel AS, Lacroix C. Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations. Clin Drug Invest 2011; 31: 435-438.
53. Lalau JD, Race J, Andreelli F et al. Metformin retention independent of renal failure in intestinal occlusion. Diabetes Metab 2001; 27: 24-28.
54. Lalau JD, Race JM. Lactic acidosis in metformin-Treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf 1999; 20: 377-384.
55. Kajbaf F, Lalau JD. The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-Associated lactic acidosis. BMC Pharmacol Toxicol 2013; 14: 22.
56. Peters N, Jay N, Barraud D et al. Metformin-Associated lactic acidosis in an intensive care unit. Crit Care 2008; 12: R149.
57. Seidowsky A, Nseir S, Houdret N et al. Metformin-Associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med 2009; 37: 2191-2196.
58. Kajbaf K, Arnouts P, de Broe M et al. Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal from around the world. Pharmacoepidemiol Drug Saf 2013; 22: 1027-1035.
59. Holstein A, Nahrwold D, Hinze S et al. Contra-indications to metformin therapy are largely disregarded. Diabet Med 1999; 16: 692-696.
60. McCormack J, Johns K, Tildesley H. Metformin's contraindications should be contraindicated. CAMJ 2005; 173: 502-504.
61. Jones G, Macklin J, Alexander W. Contraindications to the use of metformin. BMJ 2003; 4: 4-5.
62. Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 2011; 118: c380-c383.
63. Ekström N, Schiö ler L, Svensson AM et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open 2012; 2, (pii) e001076.
64. Roussel R, Travert F, Pasquet B et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010; 170: 1892-1899.
65. Whittington HJ, Hall AR, McLaughlin CP et al. Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc Drugs Ther 2013; 27: 5-16.
66. Briet C, Saraval-Gross M, Kajbaf F et al. Erythrocyte metformin levels in patients with type 2 diabetes and varying severity of chronic kidney disease. Clin Kidney J 2012; 5: 65-67.
67. Lalau JD, Vermersch A, Hary L et al. Type 2 diabetes in the elderly: an assessment of metformin (metformin in the elderly). Int J Clin Pharmacol Ther Toxicol 1990; 28: 329-932.
68. Sharif A, Baboolal K. Complications associated with new-onset diabetes after kidney transplantation. Nat Rev Nephrol 2011; 15: 34-42.
69. Yates CJ, Fourlanos S, Hjelmesaeth J et al. New-onset diabetes after kidney transplantation-changes and challenges. Am J Transplant 2012; 12: 820-828.
70. Lane JT, Odegaard DE, Haire CE et al. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation 2011; 92: e56-e57.
71. Turk T, Pietruck F, Dolff S et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 2006; 6: 842-846.
72. Pietruck F, Kribben A, Van TN et al. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. Transpl Int 2005; 18: 483-846.
73. Werzowa L, Hecking M, Haidinger M et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. Transplantation 2013; 95: 456-462.
74. Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003; 75(10 Suppl): SS3-SS24.
75. Sharif A. Should metformin be our antiglycemic agent of choice posttransplantation? Am J Transplant 2011; 11: 1376-1381.
76. Kurian B, Joshi R, Helmuth A. Effectiveness and long-Term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract 2008; 14: 979-984.
77. Larsen J. Potential risks of metformin in transplant patients. Am J Transplant 2012; 12: 795.
78. Sharif A. Metformin safety post-Transplantation-Trials and tribulations. Am J Transplant 2012; 12: 796.
79. Zelle DM, Corpeleijin E, Deinum J et al. Pancreatic beta-cell dysfunction and risk of new-onset diabetes after kidney transplantation. Diabetes Care 2013; 36: 1926-1932.
80. Hecking M, Werzowa J, Haidinger M et al. Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol Dial Transplant 2013; 28: 550-566.
81. Hecking M, Haidinger M, Dö ller D et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 2012; 23: 739-749.
82. Sharif A, de Vries APJ, Porrini E et al. (EU-NODAT working group). Clinical trials for treatment of NODAT-Time to collaborate. Transplantation 2012; 94: e23-e24.
83. Libby P. Metformin and vascular protection: a cardiologist's view. Diabetes Met 2003; 29: 6S117-6S120.
84. Pantalone K, Kattan M, Yu C et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diab Obes Metab 2012; 14: 803-809.
85. Wheeler S, Moore K, Forsberg C et al. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy. Diabetologia 2013; 56: 1934-1943.
86. Hong J, Zhang Y, Lai S et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013; 36: 1304-1311.
87. Hung A, Roumie C, Greevy R et al. Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control. Pharmacoepidemiol Drug Safety 2013; 22: 623-631.
88. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777.
89. Saenz A et al. Metformin monotherapy for diabetes mellitus. Cochrane Database Syst Rev 2005; 30: CD002966.
90. Hamnvik OP, McMahon GT. Balancing risk and benefit with oral hypoglycemic drugs. Mt Sinai J Med 2009; 76: 234-243.
91. Mak RH. Impact of end-stage renal disease on glycemic control. Semin Dial 2000; 13: 4-8.
92. Stephenson J. Diabetes drug may be associated with increase in risk of bladder cancer. JAMA 2011; 306: 143.
93. Inzucchi S, Bergenstal R, Buse J et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
94. Arnouts P, Bolignano D, Nistor I et al. Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. Nephrol Dial Transplant 2013 (e-pub ahead of print).
95. Krepinsky J, Ingram AJ, Clase CM. Prolonged SU-induces hypoglycaemia in diabetic patients with ESRD. Am J Kidney Dis 2000; 35: 500-505.
96. Brier ME, Bays H, Sloan R et al. Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes mellitus and renal failure. Am J Kidney Dis 1997; 29: 907-911.
97. Rosenkranz B, Profozic V, Metelko Z et al. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 39: 1617-1624 1996.
98. Holstein A, Plaschke A, Hammer C et al. Characteristics and time course of severe glimepiride-versus glibenclamide-induced hypoglycemia. Eur J Clin Pharmacol 59: 91-97 2003.
99. Palmer KJ, Brogden RN. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 1993; 46: 92-125.
100. Campbell DB, Adrianessens P, Hopkins YW et al. Pharmacokinetics and Metabolism of Gliclazide: A Review, In Keen H (ed). Gliclazide and the treatment of diabetes mellitus. Academic Press and the royal society of Medicine: London, UK, 1980, pp 71-82.
101. Balant L, Zahnd G, Gorgia A et al. Pharmacokinetics in man: influence of renal insufficiency. Diabetologia 1973; 9: 331-338.
102. Von Nicolai H, Brickl R, Eschey H et al. Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus. Arzneimittel Forschung 1997; 47: 247-252.
103. Harrower AD. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 1996; 31: 111-119.
104. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003; 26: 886-891.
105. Marbury TC, Ruckle JL, Hatorp V et al. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 2000; 67: 7-15.
106. Schumacher S, Abbasi I, Weise D et al. Single-And multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 2001; 57: 147-152.
107. Inoue T, Shibahara N, Miyagawa K et al. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 2003; 60: 90-95.
108. Nagai T, Imamura M, Lizuka K et al. Hypoglycemia due to nateglinide administration in diabetic patients with chronic renal failure. Diabetes Res Clin Pract 2003; 59: 191-194.
109. Mak RH, deFronzo RA. Glucose and insulin metabolism in uremia. Nephron 1992; 61: 377-382.
110. Rave K, Heise T, Pfutzner A et al. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diab Care 2001; 24: 886-890.
111. Biesenbach G, Raml A, Schmekal B et al. Decreased insulin requirement in relation to GFR in nephropathic type 1 and insulin-Treated type 2 diabetic patients. Diabet Med 2003; 20: 642-645.
112. Scirica BM, Deepak LB, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
113. White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1327-1335.
114. Bergman AJ, Cote J, Yi B et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-IV inhibitor. Diabetes Care 2007; 30: 1862-1864.
115. Chan JCN, Scott R, Arjona Ferreira JC et al. Safety and efficacy of sitagliptine in patients with type 2 diabetes and chronic renal insufficiency. Diab Obesity Met 2008; 10: 545-555.
116. He H, Tran P, Yin H et al. Absorption, metabolism, and excretion of (14C)vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 2009; 37: 536-544.
117. Scheen AJ. Pharmacokinetics of dipeptidyl peptidase inhibitors. Diabetes Obes Metab 2010; 12: 648-658.
118. Boulton DW, Li Li, Frevert EU et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011; 50: 253-265.
119. Tiwari A. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2009; 10: 1091-1104.
120. Barnett AH. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy. Adv Ther 2011; 28: 447-459.
121. Blech S, Ludwig-Schwellinger E, Graefe-Mody EU et al. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010; 38: 667-678.
122. Graefe-Mody U, Friedrich C, Port A et al. Linagliptin, a novel DPP-4 inhibitor: no need for dose adjustment in patients with renal impairment. Poster 822-P, EASD Annual Meeting, 20-24 september 2010 Stockholm, Sweden.
123. Kolterman OG, Kim DD, Shen L et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health-Syst Pharm 2005; 62: 173-181.
124. Linnebjerg H, Kothare PA, Park S et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; 64: 317-327.
125. Copley K, McCowen K, Hiles R et al. Investigation of exenatide elimination and its in vivo and in vitro degradation. Current Drug Metabolism 2006; 7: 367-374.
126. Agerso H, Jensen LB, Elbrond B et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new longacting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195-202.
127. Malm-Erjefalt M, Bjornsdottir I, Vanggaard J et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 2010; 38: 1944-1953.
128. Jacobson LV, Hindsberger C, Robson R et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009; 68: 898-905.
129. Budde K, Neumayer HH, Fritsche L et al. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003; 55: 368-374.
130. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000; 26(suppl. 4): 73-85.
131. Ahr HJ, Boberg M, Brendel E et al. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Azrneimittelforschung 1997; 47: 734-745.
132. Bakris G, Fonseca V, Sharma V et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney International 2009; 75: 1272-1277.
133. Elkinson S, Scott L. Canagliflozin: First Global Approval. Drugs 2013; 73: 979-988.
134. Dietrich E, Powell J, Taylor JR. Canagliflozin: a novel treatment option for type 2 diabetes. Drug Design, Development and Therapy 2013; 7: 1399-1408.
135. Kasichayanula S, Liu X, LaCreta F et al. Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-Transporter Type 2. Clin Pharmacokinet 2014; 53: 17-27.
136. Yale JF, Bakris G, Cariou B, Yue D et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463-473.